Teva Credit Agreement


JERUSALEM-(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced changes to its USD and JPY loan and revolving credit facilities that give it more flexibility in its leverage agreements. The leverage ratio agreements amended in credit contracts allow the leverage ratio to be gradually increased from 5.0 currently to 5.9 times in the third and fourth quarters of 2018 and gradually decline to 3.5 at December 31, 2021. This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, on changes to our USD and JPY revolving credit facilities, based on management`s current beliefs and expectations, subject to significant, known and unknown risks and uncertainties, that could lead to a clear change in our results , future performance or performance of these. expressed or implied in such forward-looking statements. The main factors that could lead to or contribute to such differences are the risks associated with: in 2018, the total amount of unpaid capital under the USD loan facility was EUR 1.6 billion. USD, the total outstanding of $1.4 billion under the JPY loan facilities and the total amount promised (as of January 31, 2018, this mechanism remained totally unlivable) of $4.5 billion to $3.0 billion under the USD revolving credit facility. The changes were supported by lenders who withheld approximately 94% of the total loans and unused commitments for the five credit facilities. and other factors that will be considered in our Annual Report on Form 20-F for the year past December 31, 2016 (“Annual Report”), including in the “Risk Factors” section and in our other applications to the U.S. Securities and Exchange Commission available from www.sec.gov and www.tevapharm.com. Forward-looking statements relate only to the date on which they are made and we undertake no obligation to update or revise any forward-looking statements or other information contained in them, whether as a result of new information, future events or otherwise. They are cautioned not to improperly rely on these forward-looking statements. Michael McClellan, Teva`s Ceo and Chief Financial Officer, said, “We welcome the continued support of our lenders and appreciate their confidence in Teva and, in particular, in our robust restructuring plan.” Mr. McClellan continued, “This change is an important part of our plan to gain additional flexibility with our credit facilities and manage our capital structure.” Teva Pharmaceutical Industries Ltd.

(NYSE and TASE: TEVA) is a global pharmacy leader that provides high-quality patient-focused healthcare solutions, used daily by approximately 200 million patients in more than 60 markets. Headquartered in Israel, Teva is the world`s leading manufacturer of generic drugs and uses its portfolio of more than 1,800 molecules to produce a wide range of generic drugs in almost all therapeutic areas. In specialized medicines, Teva has the world`s first innovative treatment for multiple sclerosis, as well as development programs for other diseases of the central nervous system, including movement disorders, migraines, pain and neurodegenerative diseases, as well as a wide range of respiratory products.

Pin It